Travere Therapeutics stock analysis
Travere Therapeutics (17R) Stock Price & Analysis
17R Stock Chart & Stats
- Day’s Range
- EUR 32.80 - EUR 33.00
- 52-Week Range
- EUR 28.60 - EUR 36.20
- Previous Close
- EUR 33.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 4.47B
- Enterprise Value
- EUR 5.72B
- Total Cash (Recent Filing)
- EUR 471.82M
- Total Debt (Recent Filing)
- EUR 616.15M
- Price to Earnings (P/E)
- ―
- Beta
- 1.39
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 0.39
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross Margin
Rapid revenue expansion and consistently exceptional gross margins indicate strong product economics and growing commercial reach. This combination can support reinvestment in the pipeline and commercialization while providing a durable foundation for improving operating leverage over the next several quarters.
FILSPARI Demand And Market Position
FILSPARI is showing substantial commercial momentum across IgA nephropathy and FSGS, while strong persistence and low switching support recurring revenue quality. Its reported preferred kidney-targeted position and expanding use across indications strengthen the product's durable market opportunity.
Improved Cash Generation
The shift to strongly positive operating and free cash flow improves Travere's ability to fund commercial expansion and clinical development internally. Although earnings remain negative, the recent cash trajectory materially strengthens operating capacity compared with the company's prior history of cash outflows.
Bears Say
High Leverage And Thin Equity
Sharp debt growth alongside substantial equity erosion leaves Travere with a very thin capital cushion and elevated leverage. This reduces financial flexibility if operating performance weakens and can constrain the company's ability to fund growth, absorb volatility, or allocate capital without balance-sheet pressure.
Persistent Operating Losses
Despite strong revenue and gross margins, Travere has not converted product economics into consistent operating profitability. The sharp deterioration in TTM EBITDA and net income suggests that operating costs and other expenses remain too high, limiting earnings durability and the value of current commercial growth.
Upcoming CEO Transition
The planned CEO change is a meaningful execution event while Travere is scaling FILSPARI and advancing multiple clinical programs. Leadership continuity will need to be maintained across commercialization, pipeline investment, and strategic priorities during a period of significant operational expansion.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics’s price range in the past 12 months?
What is Travere Therapeutics’s market cap?
When is Travere Therapeutics’s upcoming earnings report date?
How were Travere Therapeutics’s earnings last quarter?
Is Travere Therapeutics overvalued?
Does Travere Therapeutics pay dividends?
What is Travere Therapeutics’s EPS estimate?
How many shares outstanding does Travere Therapeutics have?
What happened to Travere Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Travere Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Travere Therapeutics Stock Smart Score
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Dube
- Employees
- 497
- Website
- www.travere.com
- Address
- 3611 Valley Centre Drive, San Diego, CA, 92130, US
Travere Therapeutics (17R) Earnings & Revenues
17R Company Deck
17R Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by record FILSPARI sales, approximately 120% year-over-year product growth, strong demand and persistence across IgA nephropathy and FSGS, encouraging clinical data, and continued pipeline and patent progress. The main challenges were expected fourth-quarter inventory normalization, a slight sequential decline in IgA nephropathy demand, anticipated gross-to-net pressure, substantial licensing-related expense, and the upcoming CEO transition. Positive operating momentum and pipeline progress significantly outweighed the stated headwinds.
View all DE:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 6 |
| Technical Analysis | 2 | 1 | 4 |
| Moving Averages | 7 | 3 | 2 |
